Mythic Therapeutics - About the company
Mythic Therapeutics is a series B company based in Waltham (United States), founded in 2017 by Brian Fiske and Nimish Gera. It operates as a Developer of antibody-drug conjugates for the treatment of cancer. Mythic Therapeutics has raised $103M in funding from Viking Global Investors. The company has 3413 active competitors, including 1138 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of antibody-drug conjugates for the treatment of cancer. The company has FateControl technology is used for the development of ADCs and also increases ADC uptake in cancerous cells while avoiding payload release in normal cells.
- Website
- mythictx.com
- Email ID
- *****@mythictx.com
- Registered Address
- 100 Beaver Street, Waltham, MA 02453 USA
Key Metrics
Founded Year
2017
Location
Waltham, United States
Stage
Series B
Total Funding
$103M in 1 round
Latest Funding Round
Investors
Ranked
223rd among 3413 active competitors
Employee Count
57 as on Feb 17, 2025
Similar Companies
Legal entities associated with Mythic Therapeutics
Mythic Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Mythic Therapeutics, Inc. CIN: 81-4289051 , United States, Active | Nov 23, 2016 | - | 12 (As on Dec 31, 2021) | - |
Sign up to download Mythic Therapeutics' company profile
Mythic Therapeutics's funding and investors
Mythic Therapeutics has raised a total funding of $103M over 1 round. Its latest funding round was a Series B round on Dec 15, 2021 for $*****. 9 investors participated in its latest round. Mythic Therapeutics has 14 institutional investors.
Here is the list of recent funding rounds of Mythic Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 15, 2021 | 6455894 | Series B | 2300517 | 7270745 | 8831085 | 3180156 |
Access funding benchmarks and valuations. Sign up today!View details of Mythic Therapeutics's funding rounds and investors
Mythic Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Mythic Therapeutics are Brian Fiske and Nimish Gera.
Here are the details of Mythic Therapeutics' key team members:
- Brian Fiske: Co-Founder, President, and CEO of Mythic Therapeutics.
- Nimish Gera: Scientific Co-Founder, Vice President, Biologics of Mythic Therapeutics.
View details of Mythic Therapeutics's Founder profiles and Board Members
Mythic Therapeutics' employee count trend
Mythic Therapeutics has 57 employees as of Feb 25. Here is Mythic Therapeutics's employee count trend over the years:
Uncover Mythic Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mythic Therapeutics's Competitors and alternates
Top competitors of Mythic Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Mythic Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
223rd |  Mythic Therapeutics 2017, Waltham (United States), Series B | Developer of antibody-drug conjugates for the treatment of cancer | $103M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Mythic Therapeutics's competitors? Click here to see the top ones
Mythic Therapeutics's Investments and acquisitions
Mythic Therapeutics has made no investments or acquisitions yet.
Reports related to Mythic Therapeutics
Here is the latest report on Mythic Therapeutics's sector:
News related to Mythic Therapeutics
Media has covered Mythic Therapeutics for 1 event in last 1 year, It was about company updates.
•
Mythic Therapeutics shuts down, ditching ADC trial as funding dries upEndpoints•Dec 17, 2025•Mythic Therapeutics
•
Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire•Jun 04, 2024•Mythic Therapeutics
•
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive OfficerBusiness Wire•Mar 28, 2024•Mythic Therapeutics
•
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET OverexpressionBusiness Wire•Sep 26, 2023•Mythic Therapeutics
•
•
Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual MeetingPipelinereview•Apr 19, 2023•Mythic Therapeutics
•
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for theACROFAN•Apr 04, 2023•Mythic Therapeutics
•
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic TherapeuticsPR Newswire•Feb 10, 2023•Nona Biosciences, Mythic Therapeutics
•
Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development OfficerBusiness Wire•Aug 23, 2022•Mythic Therapeutics
•
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B FinancingBusiness Wire•Dec 15, 2021•Mythic Therapeutics, Viking Global Investors, Venrock, Foresite Capital and 6 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Mythic Therapeutics
Explore our recently published companies
- Belium Medical - Spain based, Unfunded company
- Temecula Printing - Unfunded company
- Flexa Cloud - Brazil based, 2008 founded, Unfunded company
- Unsaid - 2026 founded, Unfunded company
- Excelhealthtech - India based, Unfunded company
- Alignment Mindset - Unfunded company
